A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study

Author:

Komatsu Hiroaki1ORCID,Matsumoto Koji2ORCID,Morita Mitsunori2,Nagasawa Takayuki3,Nishio Hiroshi4,Suzuki Jiro5,Nishio Shin6ORCID,Kobara Hisanori7,Yunokawa Mayu8,Ariyoshi Kazuya9,Hirayama Takashi10,Tokunaga Hideki11,Ukita Masayo12,Yoriki Kaori13,Mori‐Uchino Mayuyo14,Furusawa Akiko15,Togami Shinichi16,Nakamura Hiroko17,Ishikawa Mitsuya18,Satoh Toyomi19

Affiliation:

1. Department of Obstetrics and Gynecology Tottori University School of Medicine Yonago Tottori Japan

2. Department of Medical Oncology Hyogo Cancer Center Akashi Hyogo Japan

3. Department of Obstetrics and Gynecology Iwate Medical University School of Medicine Morioka Iwate Japan

4. Department of Obstetrics and Gynecology Keio University School of Medicine Tokyo Japan

5. Department of Obstetrics and Gynecology The Jikei University School of Medicine Tokyo Japan

6. Department of Obstetrics and Gynecology Kurume University School of Medicine Kurume Japan

7. Department of Obstetrics and Gynecology Shinshu University Nagano Japan

8. Department of Gynecology The Cancer Institute Hospital of JFCR Tokyo Japan

9. Department of Gynecology Service National Kyushu Cancer Center Fukuoka Japan

10. Department of Obstetrics and Gynecology Juntendo University Hospital Tokyo Japan

11. Department of Gynecology Tohoku University Graduate School of Medicine Sendai Japan

12. Department of Gynecology and Obstetrics, Graduate School of Medicine Kyoto University Kyoto Japan

13. Department of Obstetrics and Gynecology, Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan

14. Department of Obstetrics and Gynecology, Faculty of Medicine The University of Tokyo Tokyo Japan

15. Department of Gynecology Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital Tokyo Japan

16. Department of Obstetrics and Gynecology, Faculty of Medicine Kagoshima University Kagoshima Japan

17. Department of Obstetrics and Gynecology National Hospital Organization Kure Medical Center and Chugoku Cancer Center Kure Japan

18. Department of Gynecology, National Cancer Center Hospital Tokyo Japan

19. Department of Obstetrics and Gynecology, Institute of Medicine University of Tsukuba Tsukuba Japan

Abstract

AbstractIntroductionHypersensitivity reactions (HSRs) to chemotherapy are serious adverse events associated with cancer drug therapy and can occur with any antitumor drug. This study investigated the safety and efficacy of carboplatin desensitization therapy in Japan and established a method for treating carboplatin HSRs.MethodsPatients diagnosed with gynecological (ovarian, endometrial, or cervical) cancers who underwent carboplatin desensitization therapy between 2016 and 2020 at the Gynecologic Cancer Study Group of Japan Clinical Oncology Group were included. The carboplatin desensitization therapy at each institution and the implementation cases were registered in an online case report form.ResultsThis retrospective study enrolled 136 patients (ovarian, 108; endometrial, 17; and cervical cancer, 11). Pre‐existing allergies were present in 37 (27.2%) patients, and 32 (23.5%) patients exhibited prodromal symptoms during treatment before HSR onset. Erythema was the most common symptom at HSR onset, affecting 93 (68.4%) patients, followed by itching in 72 (52.9%) patients and decreased oxygen saturation in 43 (31.6%) patients. Loss of consciousness occurred in three (2.2%) patients. The most common timing of HSR onset was during the first recurrence treatment (47%). The mean total carboplatin dose until HSR onset was 7331 (2620–18,282) mg, and the mean number of doses was 14 (4–63). Desensitization treatment was completed in 75% of cases, and breakthrough HSRs occurred in 25% (34/136). No deaths occurred in the study cohort. The risk factors for HSRs were not identified.ConclusionAlthough carboplatin desensitization therapy has high success rates in Japan, erythema and pruritus are important HSRs to consider.

Publisher

Wiley

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Carboplatin;Reactions Weekly;2024-04-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3